AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25213052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole treatment
Number of subjects: 110
Study 25213052 — intervention group
Group type: COMPARATOR
Intervention: EBC pH measurement
Number of subjects: 110
Study 21789654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures with slow-absorbing material (PDS 2.0)
Number of subjects: 264
Study 21789654 — intervention group
Group type: COMPARATOR
Intervention: Tissue glue (Histoacryl)
Number of subjects: 264
Study 19618317 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment for 8 weeks
Number of subjects: 10
Study 19618317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 10
Study 17243866 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamins K(1) and D(3) plus calcium
Number of subjects: 244
Study 17243866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(1) (200 microg/day)
Number of subjects: 244
Study 17243866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (10 microg or 400 IU) plus calcium (1000 mg/day)
Number of subjects: 244
Study 17243866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 15331942 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 209
Study 15331942 — intervention group
Group type: COMPARATOR
Intervention: Citrate plus low-dose heparin
Number of subjects: 209
Study 11978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (100 to 200 mg/day in the initial phase)
Number of subjects: 0
Study 11978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (mainly as maintenance treatment)
Number of subjects: 0
Study 11978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of corticosteroids with cytotoxic drugs (azathioprine, cyclophosphamide, chlorambucil)
Number of subjects: 0
Study 11978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids with sulfa drugs (dapsone, clofazimine, minocycline, thalidomide)
Number of subjects: 0
Study 11978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of granulocyte-macrophage colony-stimulating factor, intravenous immunoglobulins, plasmapheresis
Number of subjects: 0
Study 11978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin transplants (split-skin grafts or autologous keratinocyte grafts)
Number of subjects: 0
Study 11978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical therapy with modern wound dressings
Number of subjects: 0
Study 11978136 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibacterial therapy
Number of subjects: 0
Study 9212138 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (n = 11)
Number of subjects: 23
Study 9212138 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia (n = 12)
Number of subjects: 23
Study 8221837 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPV produced by China
Number of subjects: 0
Study 8221837 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPV produced by Yugoslavia
Number of subjects: 0
Study 8221837 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPV produced by Belgium
Number of subjects: 0
Study 3114397 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative TPN
Number of subjects: 92
Study 3114397 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid and electrolyte support
Number of subjects: 92
Study 31832638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole treatment (CTX-T)
Number of subjects: 63
Study 31832638 — intervention group
Group type: COMPARATOR
Intervention: No cotrimoxazole treatment (CTX-N)
Number of subjects: 63
Study 29424609 — intervention group
Group type: EXPERIMENTAL
Intervention: HCC with incentive
Number of subjects: 82
Study 29424609 — intervention group
Group type: COMPARATOR
Intervention: HCC without incentive
Number of subjects: 82
Study 29424609 — intervention group
Group type: COMPARATOR
Intervention: LCC
Number of subjects: 82
Study 25398661 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2-mm superior clear corneal incision (SCCI)
Number of subjects: 151
Study 25398661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8-mm superior clear corneal incision (SCCI)
Number of subjects: 151
Study 25398661 — intervention group
Group type: COMPARATOR
Intervention: Control 3.2-mm superior clear corneal incision (SCCI)
Number of subjects: 151
Study 24986744 — intervention group
Group type: EXPERIMENTAL
Intervention: IBCL seeds
Number of subjects: 140
Study 24986744 — intervention group
Group type: COMPARATOR
Intervention: Loose seeds
Number of subjects: 140
Study 24986744 — intervention group
Group type: EXPERIMENTAL
Intervention: IBCL seeds and Loose seeds
Number of subjects: 140
Study 22074491 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem and health locus of control intervention
Number of subjects: 144
Study 22074491 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study 19535429 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) (8 g oil/d)
Number of subjects: 55
Study 19535429 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (SAF) (8 g oil/d)
Number of subjects: 55
Study 18089983 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session peer mentoring intervention
Number of subjects: 966
Study 18089983 — intervention group
Group type: COMPARATOR
Intervention: 8-session video discussion intervention (control condition)
Number of subjects: 966
Study 15223199 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse callosotomy
Number of subjects: 14
Study 15223199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal callosotomy
Number of subjects: 14
Study 15223199 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 11449087 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen group (21 tablets with 20 microg of ethinyl‐estradiol and 150 mg of desogestrel for 21 days, followed by 2 placebo tablets and 5 ethinyl‐estradiol tablets of 10 microg each)
Number of subjects: 56
Study 11449087 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (21 tablets with 20 microg of ethinyl‐estradiol and 150 mg of desogestrel for 21 days, followed by 7 placebo tablets)
Number of subjects: 56
Study 9749850 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 672
Study 9749850 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 672
Study 7839843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral components made of titanium alloy
Number of subjects: 19
Study 7839843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metallic implant)
Number of subjects: 19
Study 2835245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-648,051 (35, 52.5, and 70 mg/5 min infusion)
Number of subjects: 20
Study 2835245 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized L-648,051 (0.1 to 1.6 mg)
Number of subjects: 20
Study 1677015 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 30
Study 1677015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 366803 — intervention group
Group type: EXPERIMENTAL
Intervention: O2
Number of subjects: 3
Study 366803 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2
Number of subjects: 3
Study 366803 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 3
Study 30895637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional application of medical grade honey (MGH)
Number of subjects: 127
Study 30895637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 31511279 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligosaccharide-sialic acid (OS) preparation
Number of subjects: 0
Study 31511279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27687823 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy group (EG) - home‐based progressive strength and aerobic training program for 12 months
Number of subjects: 98
Study 27687823 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG) - received only oral and written instructions of exercises
Number of subjects: 98
Study 27687823 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy group (EG)
Number of subjects: 98
Study 27687823 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UCG)
Number of subjects: 98
Study 26112220 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management Support (SMS) delivered by practice nurses
Number of subjects: 264
Study 26112220 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by practice nurses
Number of subjects: 264
Study 23303106 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley bulb plus vaginal misoprostol
Number of subjects: 123
Study 23303106 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol alone
Number of subjects: 123
Study 21332891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus sporogenes (Bacillus coagulans)
Number of subjects: 148
Study 21332891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 148
Study 19165529 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH ER (10 mg/day to 60 mg/day)
Number of subjects: 359
Study 19165529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 17130747 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 0
Study 17130747 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula enriched in alpha-lactalbumin with higher GMP
Number of subjects: 0
Study 17130747 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula enriched in alpha-lactalbumin with lower GMP
Number of subjects: 0
Study 15123495 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (CC) intervention
Number of subjects: 120
Study 15123495 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) control condition
Number of subjects: 120
Study 11433049 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 291
Study 11433049 — intervention group
Group type: COMPARATOR
Intervention: Self-Help (SH)
Number of subjects: 291
Study 9229881 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1 mg/kg bolus followed by continuous infusion 0.1 mg/kg/h
Number of subjects: 0
Study 9229881 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg bolus followed by continuous infusion 0.2 mg/kg/h
Number of subjects: 0
Study 9229881 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.3 mg/kg bolus followed by continuous infusion 0.3 mg/kg/h
Number of subjects: 0
Study 9229881 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal application of 100 mg indomethacin
Number of subjects: 0
Study 8387576 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cisplatin (SDCP) 50 mg/m2 days 1 and 8 on a 28-day cycle for eight cycles
Number of subjects: 356
Study 8387576 — intervention group
Group type: COMPARATOR
Intervention: High-dose cisplatin (HDCP) 100 mg/m2 days 1 and 8 for four cycles
Number of subjects: 356
Study 8387576 — intervention group
Group type: COMPARATOR
Intervention: High-dose cisplatin plus mitomycin (HDCP-M) 8 mg/m2 day 1
Number of subjects: 356
Study 2893636 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (mean daily dose 77 mg)
Number of subjects: 24
Study 2893636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (mean daily dose 62 mg)
Number of subjects: 24
Study 31722679 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with ropivacaine wound infiltration and intravenous flurbiprofen axetil
Number of subjects: 0
Study 31722679 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28568974 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg mesalazine tablets (3.2 g oral mesalazine, administered as two 1600 mg tablets once daily)
Number of subjects: 817
Study 28568974 — intervention group
Group type: COMPARATOR
Intervention: 400 mg mesalazine tablets (4 tablets twice daily)
Number of subjects: 817
Study 26571066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-Velpatasvir
Number of subjects: 624
Study 26571066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 23219177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 692
Study 23219177 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 692
Study 22011376 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium hydroxide (KOH) 10%
Number of subjects: 0
Study 22011376 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium hydroxide (KOH) 15%
Number of subjects: 0
Study 22011376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 22011376 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium hydroxide (KOH) 10% and 15%
Number of subjects: 0
Study 18695660 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions (GTs)
Number of subjects: 74
Study 17699358 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 13
Study 17699358 — intervention group
Group type: COMPARATOR
Intervention: Lemonade
Number of subjects: 13
Study 17699358 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 13
Study 12133554 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 30
Study 12133554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10434263 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 0
Study 10434263 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsers
Number of subjects: 0
Study 10434263 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 7755647 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 18
Study 7755647 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18
Study 2267246 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-nurse contract
Number of subjects: 41
Study 2267246 — intervention group
Group type: COMPARATOR
Intervention: Control group orientation to unit routines
Number of subjects: 41
Study 7241435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 25 1/min
Number of subjects: 8
Study 7241435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 80 1/min
Number of subjects: 8
Study 7241435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 25 1/min with 20% vital capacity
Number of subjects: 8
Study 7241435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 25 1/min with 50% vital capacity
Number of subjects: 8
Study 7241435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 25 1/min with 80% vital capacity
Number of subjects: 8
Study 7241435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 80 1/min with 20% vital capacity
Number of subjects: 8
Study 7241435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 80 1/min with 50% vital capacity
Number of subjects: 8
Study 7241435 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg terbutaline sulphate inhaled at 80 1/min with 80% vital capacity
Number of subjects: 8
Study 31678536 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-targeted DNA vaccine of Vibrio mimicus
Number of subjects: 0
Study 30599693 — intervention group
Group type: EXPERIMENTAL
Intervention: Physics-based statistics modeling
Number of subjects: 0
Study 30599693 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26306418 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural therapy intervention provided by trained pharmacists (stimulus control and sleep restriction) over three pharmacy visits (baseline, 1 and 3 months follow-up)
Number of subjects: 46
Study 24878363 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist heat (MHG)
Number of subjects: 198
Study 24878363 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry heat (DHG)
Number of subjects: 198
Study 24878363 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 198
Study 21952697 — intervention group
Group type: COMPARATOR
Intervention: Normal-birth-weight (NBW) infants, n=183
Number of subjects: 66
Study 19833998 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent housing, vocational training, and work
Number of subjects: 206
Study 19833998 — intervention group
Group type: COMPARATOR
Intervention: Abstinence-contingent housing, vocational training, work, plus cognitive behavioral day treatment
Number of subjects: 206
Study 19833998 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive weeks of abstinence during treatment
Number of subjects: 206
Study 19833998 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age and male gender
Number of subjects: 206
Study 17390417 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 66
Study 17390417 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 66
Study 15658951 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN4096BS 2.5 mg
Number of subjects: 7
Study 15658951 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN4096BS 10 mg
Number of subjects: 7
Study 15658951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 15658951 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN4096BS (2.5 mg and 10 mg)
Number of subjects: 7
Study 12409542 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800
Study 12409542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study 9931170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking period
Number of subjects: 39
Study 7776273 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 78
Study 7776273 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 78
Study 2181623 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable antacid tablet (30 mmol) four times daily
Number of subjects: 91
Study 2181623 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg cimetidine twice daily
Number of subjects: 91
Study 2181623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 7418711 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of hydrochlorothiazide daily
Number of subjects: 27
Study 7418711 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of reserpine daily
Number of subjects: 27
Study 31812464 — intervention group
Group type: EXPERIMENTAL
Intervention: IVACFLU-A/H5N1 vaccine (15 mcg)
Number of subjects: 930
Study 31812464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 30455160 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily lottery incentives tied to achievement of weight loss goals
Number of subjects: 344
Study 30455160 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored environmental strategies around food intake and physical activity
Number of subjects: 344
Study 30455160 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of incentives and environmental strategies
Number of subjects: 344
Study 30455160 — intervention group
Group type: COMPARATOR
Intervention: Standard employee wellness benefits and weigh-ins every 6 months
Number of subjects: 344
Study 29045770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 75
Study 29045770 — intervention group
Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 75
Study 25845462 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust Before Restraint training intervention
Number of subjects: 274
Study 25845462 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 274
Study 24506910 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin D supplementation (2000 IU/day)
Number of subjects: 750
Study 24506910 — intervention group
Group type: COMPARATOR
Intervention: Standard dose vitamin D supplementation (400 IU/day)
Number of subjects: 750
Study 22306855 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV4 vaccine (standard schedule: 0, 2, 6 months)
Number of subjects: 200
Study 22306855 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV4 vaccine (modified schedule: 0, 3, 6 months)
Number of subjects: 200
Study 18953552 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B nasal spray (5 mg/ml)
Number of subjects: 30
Study 18953552 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (lacking amphotericin B)
Number of subjects: 30
Study 17671281 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for up to 14 weeks
Number of subjects: 4041
Study 15895838 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal stabilization splints
Number of subjects: 21
Study 15895838 — intervention group
Group type: COMPARATOR
Intervention: Palatal splints
Number of subjects: 21
Study 12061619 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed coaching regarding CBCA
Number of subjects: 0
Study 12061619 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninformed coaching regarding CBCA
Number of subjects: 0
Study 12061619 — intervention group
Group type: EXPERIMENTAL
Intervention: Witness condition
Number of subjects: 0
Study 12061619 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspect condition
Number of subjects: 0
Study 12061619 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills correlation
Number of subjects: 0
Study 9593411 — intervention group
Group type: EXPERIMENTAL
Intervention: High-heeled shoes
Number of subjects: 20
Study 9593411 — intervention group
Group type: COMPARATOR
Intervention: Barefoot walking
Number of subjects: 20
Study 1521362 — intervention group
Group type: EXPERIMENTAL
Intervention: Omron HEM‐719K
Number of subjects: 18
Study 1521362 — intervention group
Group type: EXPERIMENTAL
Intervention: Omron HEM‐812F
Number of subjects: 18